Synapse

← Cancer Treatment and Research Communications

Papers in Cancer Treatment and Research Communications

Page 14 · newest first

  1. Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistanceCancer Treatment and Research Communications · 2022
  2. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancerCancer Treatment and Research Communications · 2022
  3. Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer TherapyCancer Treatment and Research Communications · 2022
  4. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancerCancer Treatment and Research Communications · 2022
  5. Use of immunotherapy in clinical management of genitourinary cancers – a reviewCancer Treatment and Research Communications · 2022
  6. Evaluation of clinical prognostic variables on short-term outcome for colorectal cancer surgery: An overview and minimum datasetENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2022
  7. Ionizing radiation and cancer: The failure of the risk modelCancer Treatment and Research Communications · 2022
  8. Problem-solving skills training in adult cancer survivors: Bright IDEAS-AC pilot studyCancer Treatment and Research Communications · 2022
  9. Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancerCancer Treatment and Research Communications · 2022
  10. COVID-19 vaccine associated axillary lymphadenopathy – A systematic reviewCancer Treatment and Research Communications · 2022
  11. New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathyCancer Treatment and Research Communications · 2022
  12. Prediction of lymphovascular space invasion in cervical carcinoma using diffusion kurtosis imagingCancer Treatment and Research Communications · 2022
  13. The analysis of breast cancer survival in East Azerbaijan province of Iran; prognostic impact of chemotherapy and hormone therapy protocolsCancer Treatment and Research Communications · 2022
  14. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung CancerCancer Treatment and Research Communications · 2022
  15. Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcomeCancer Treatment and Research Communications · 2022
  16. Optimizing risk factors influence Intensive Care stay after Hyperthermic Intraperitoneal Chemotherapy? An observational cohort studyCancer Treatment and Research Communications · 2022
  17. Polymer-based drug delivery systems for anticancer drugs: A systematic reviewCancer Treatment and Research Communications · 2022
  18. Assessment of knowledge, attitude, practices and distress level of cancer patients in COVID-19 pandemic: A cross-sectional studyCancer Treatment and Research Communications · 2022
  19. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before surgery in patients with locally advanced rectal cancerCancer Treatment and Research Communications · 2022
  20. Current approach to Waldenström MacroglobulinemiaCancer Treatment and Research Communications · 2022
  21. Circulating tumor DNA for breast cancer: Review of active clinical trialsCancer Treatment and Research Communications · 2022
  22. Non-urothelial and urothelial variants of bladder cancerCancer Treatment and Research Communications · 2022
  23. Physical Exercise and Tumor Energy MetabolismCancer Treatment and Research Communications · 2022
  24. Efficacy of Bacillus clausii UBBC - 07 spores in the amelioration of oral mucositis in head and neck cancer patients undergoing radiation therapyCancer Treatment and Research Communications · 2022
  25. Epithelial ovarian cancer: Review articleCancer Treatment and Research Communications · 2022
  26. Doxycycline inhibits the progression of metastases in early-stage osteosarcoma by downregulating the expression of MMPs, VEGF and ezrin at primary sitesCancer Treatment and Research Communications · 2022
  27. Exploring the prognostic impact of tumor sidedness in ovarian cancer: A population-based survival analysis of over 10,000 patientsCancer Treatment and Research Communications · 2022
  28. Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapyCancer Treatment and Research Communications · 2022
  29. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trialsCancer Treatment and Research Communications · 2022
  30. Impact of the COVID-19 outbreak on prostate cancer care in the NetherlandsCancer Treatment and Research Communications · 2022
  31. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS studyCancer Treatment and Research Communications · 2022
  32. Effect of docosahexaenoic acid as a chemopreventive agent on experimentally induced hamster buccal pouch carcinogenesisCancer Treatment and Research Communications · 2022
  33. Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysisCancer Treatment and Research Communications · 2022
  34. Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studiesCancer Treatment and Research Communications · 2022
  35. Development of a prognostic gene signature for hepatocellular carcinomaCancer Treatment and Research Communications · 2022
  36. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapyCancer Treatment and Research Communications · 2022
  37. Earlier diagnosis of lung cancerCancer Treatment and Research Communications · 2022
  38. Current management and recent progress in desmoid tumorsCancer Treatment and Research Communications · 2022
  39. Subclonal landscape of cancer drives resistance to immune therapyCancer Treatment and Research Communications · 2022
  40. Abdominoperineal Excision in current eraCancer Treatment and Research Communications · 2022
  41. Association between Allium vegetables and the risk of non-digestive tract cancer: A systematic review and meta-analysis of cohort and case-control studiesCancer Treatment and Research Communications · 2022
  42. Clinical value of CT-guided biopsy of small (≤1.5 cm) suspicious lung nodules: Diagnostic accuracy, molecular characterization and long-term clinical outcomesCancer Treatment and Research Communications · 2022
  43. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer GroupCancer Treatment and Research Communications · 2022
  44. Recurrent extramedullary plasmacytomas without multiple myeloma: A case report with review of the literature.Cancer Treatment and Research Communications · 2022
  45. Dynamic 18F-FET PET/CT to differentiate recurrent primary brain tumor and brain metastases from radiation necrosis after single-session robotic radiosurgeryCancer Treatment and Research Communications · 2022
  46. First-trimester miscarriage in the background of endometrial carcinomaCancer Treatment and Research Communications · 2022
  47. Filipinos’ attitudes, barriers, and enablers on colorectal cancer screening: Insights from a qualitative research studyCancer Treatment and Research Communications · 2022
  48. Detection improvement of gliomas in hyperspectral imaging of protoporphyrin IX fluorescence – in vitro comparison of visual identification and machine thresholdsCancer Treatment and Research Communications · 2022
  49. Small cell neuroendocrine carcinoma of vagina: Report of a unique case with literature reviewCancer Treatment and Research Communications · 2022
  50. Targeting inhibitor of apoptosis proteins (IAPs) with IAP inhibitors sensitises malignant rhabdoid tumour cells to cisplatinCancer Treatment and Research Communications · 2022